- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05030779
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus
Clinical Trial for the Safety and Efficacy of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Autoimmune diseases only show local pathological damage, but more often systemic lesions. If not diagnosed and treated in time or poorly controlled, a risk of disability or even death as the course of the disease progresses. Studies have shown that B cells can present their own antigens to autoimmune T cells to promote the release of inflammatory factors, or they can differentiate into plasma cells to release autoantibodies, and play an important role in the occurrence and progression of autoimmune diseases. In recent years, it has become a major research focus to deplete B cells in patients or inhibit B cell function. This research focuses on CAR-T cells killing B cells. In 2019, Kansal and others released their team's in vivo experiments to prove that CD19 CAR-T cells have achieved significant and long-lasting effects in the treatment of systemic lupus erythematosus. This fully reflects the application prospects of CAR-T cells in autoimmune diseases.
Based on the current research progress, our center intends to conduct research on the safety and effectiveness of CD19/BCMA CAR-T cells in the treatment of refractory systemic lupus erythematosus.
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- The First Affiliated Hospital,College of Medicine, Zhejiang University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Systemic lupus erythematosus with positive CD19/BCMA expression , and the conventional treatment is not effective and (or) no effective treatment
- Estimated survival time> 12 weeks;
- Patients had a negative urine pregnancy test before the start of administration and agreed to take effective contraceptive measures during the test period until the last follow-up;
- Patients or their legal guardians volunteer to participate in the study and sign the informed consent.
Exclusion Criteria:
Subjects with any of the following exclusion criteria were not eligible for this trial:
- History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases;
- Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
- Pregnant (or lactating) women;
- Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis);
- Active infection of hepatitis B virus or hepatitis C virus;
- Concurrent therapy with systemic steroids within 2 weeks prior to screening, except for the patients recently or currently receiving in haled steroids;
- Creatinine>2.5mg/dl, or ALT / AST > 3 times of normal amounts, or bilirubin>2.0 mg/dl;
- Other uncontrolled diseases that were not suitable for this trial;
- Patients with HIV infection;
- Any situations that the investigator believes may increase the risk of patients or interfere with the results of study
- Platelets ≥30×10E9/L, and absolute lymphocyte count ≥1.0×10E9/L
- Methylprednisolone (maximum dose 1mg/kg) or prednisone (maximum dose 1.25mg/kg) instead of immunosuppressive agents to control the disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment of SLE
Experimental:Administration of CD19/BCMA CAR T-cells A dose levels of 1-4*10E6/kg are administrated for each subject.
|
Drug: CD19/BCMA CAR T-cells Each subject receive CD19/BCMA CAR T-cells by intravenous infusion Other Name: CD19/BCMA CAR T-cells injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting toxicity (DLT)
Time Frame: Baseline up to 28 days after CD19/BCMA CAR T-cells infusion
|
Adverse events assessed according to NCI-CTCAE v5.0 criteria
|
Baseline up to 28 days after CD19/BCMA CAR T-cells infusion
|
Incidence of treatment-emergent adverse events (TEAEs)
Time Frame: Up to 90 days after CD19/BCMA CAR T-cells infusion
|
Incidence of treatment-emergent adverse events [Safety and Tolerability]
|
Up to 90 days after CD19/BCMA CAR T-cells infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Autoantibody detection
Time Frame: Up to 90 days after CD19/BCMA CAR T-cells infusion
|
Detect the lupus erythematosus antibody titer in vivo
|
Up to 90 days after CD19/BCMA CAR T-cells infusion
|
Concentration of CAR-T cells
Time Frame: From admission to the end of the follow-up, up to 2 years
|
In peripheral blood and bone marrow
|
From admission to the end of the follow-up, up to 2 years
|
Objective Response Rate, ORR
Time Frame: In 3 months of CD19/BCMA CAR-T cell infusion
|
Proportion of subjects with complete or partial remission
|
In 3 months of CD19/BCMA CAR-T cell infusion
|
Disease control rate, DCR
Time Frame: From Day 28 CD19/BCMA CAR-T infusion up to 2 years
|
The percentage of patients with remission and stable disease after treatment in the total evaluable cases.
|
From Day 28 CD19/BCMA CAR-T infusion up to 2 years
|
Duration of remission, DOR
Time Frame: 24 months post CD19/BCMA CAR-T cells infusion
|
The time from the first assessment of remission or partial remission of the disease to the first assessment of disease progression or death from any cause
|
24 months post CD19/BCMA CAR-T cells infusion
|
Progression-free survival, PFS
Time Frame: 24 months post CD19/BCMA CAR-Tcells infusion
|
The time from cell reinfusion to the first assessment of disease progression or death from any cause
|
24 months post CD19/BCMA CAR-Tcells infusion
|
Overall survival, OS
Time Frame: From CD19/BCMA CAR-T infusion to death,up to 2 years
|
The time from the cell reinfusion to death due to any cause
|
From CD19/BCMA CAR-T infusion to death,up to 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CD19/BCMA-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autoimmune Diseases
-
SanofiCompletedHealthy Volunteers | Autoimmune DisorderUnited States
-
National Eye Institute (NEI)Completed
-
Sinocelltech Ltd.Not yet recruiting
-
TakedaCompletedAutoimmune DiseaseUnited Kingdom
-
Ziv HospitalUnknownAutoimmune DiseaseIsrael
-
The Eye Center and The Eye Foundation for Research...CompletedAutoimmune Polyglandular Syndrome Type I | Autoimmune Keratitis
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedAutoimmune DisordersUnited States
-
Fundación Pública Andaluza Progreso y SaludKarolinska Institutet; Eli Lilly and Company; Medical University of Vienna; Sanofi and other collaboratorsCompletedSystemic Autoimmune DiseasesFrance, Belgium, Germany, Italy, Spain, Switzerland
-
Muğla Sıtkı Koçman UniversityCompletedMultiple Sclerosis | Telerehabilitation | Autoimmune Disorder | Exercise ProgramTurkey
-
Ruijin HospitalRecruiting
Clinical Trials on Assigned Interventions CD19/BCMA CAR T-cells
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingAutoimmune Diseases | SclerodermaChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingAutoimmune Diseases | Lupus Nephritis | Immune NephritisChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingAutoimmune Diseases | Sjogren's SyndromeChina
-
University College, LondonActive, not recruitingMultiple MyelomaUnited Kingdom
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingVasculitis | Amyloidosis | Autoimmune Hemolytic Anemia | POEMS SyndromeChina
-
The First Affiliated Hospital of Nanchang UniversityUnknownRelapsed or Refractory Multiple MyelomaChina
-
RenJi HospitalGracell Biotechnology Shanghai Co., Ltd.RecruitingCAR-T Cell TherapyChina
-
Zhejiang UniversityGracell Biotechnology Shanghai Co., Ltd.Recruiting
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingAcute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia RefractoryChina
-
Ting Chang, MDNot yet recruiting